anti cancer
-
Astrazeneca and Merck Collaborate to Investigate Anticancer Regimen
AstraZeneca and Merck have announced a collaboration to research a combination anticancer regimen composed of two investigational compounds – MK-2206 from the latter and AZD6244 (ARRY-886*) from the former. Preclinical evidence indicates that t…
anti cancer | 04 June 2009
